NCT03643068 - Phase 1A Study of the Safety of KSP/QRH Dimer | Biotech Hunter

Enrollment

26

Participants

Timeline

Start Date

August 22, 2018

Primary Completion Date

October 27, 2018

Study Completion Date

October 27, 2018

Conditions

Healthy Adults

Interventions

DRUG

KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg

The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence \[Lys-Ser-Pro-Asn-Pro-Arg-Phe\] and \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a PEG3, Lys and Cys linker \[PEG3\]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (0.6 mg dose).

DRUG

KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg

The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence \[Lys-Ser-Pro-Asn-Pro-Arg-Phe\] and \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a PEG3, Lys and Cys linker \[PEG3\]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (1.8 mg dose).

Trial Locations (1)

48109

University of Michigan, Ann Arbor